The HOPE study. Ramipril lowered cardiovascular risk, but vitamin E did not

Area of Science:

• Cardiology
• Pharmacology
• Endocrinology

Background:

• Atherosclerotic disease and diabetes pose significant cardiovascular risks.
• Angiotensin-converting enzyme (ACE) inhibitors are commonly used for cardiovascular risk management.
• The role of antioxidants like vitamin E in cardiovascular prevention remains an area of investigation.

Purpose of the Study:

• To evaluate the efficacy of ramipril, an ACE inhibitor, in reducing major cardiovascular events.
• To assess the impact of vitamin E on cardiovascular outcomes.
• To investigate the effects of ramipril on diabetic nephropathy and the incidence of new-onset diabetes.

Main Methods:

• The Heart Outcomes Prevention Evaluation (HOPE) study was a large-scale, randomized, placebo-controlled trial.
• Participants included patients with known atherosclerosis or diabetes plus cardiovascular risk factors, excluding those with heart failure.
• Interventions involved ramipril and vitamin E supplementation.

Main Results:

• Ramipril significantly reduced the risk of atherosclerotic disease events and death, independent of blood pressure effects.
• Ramipril use led to a reduced risk of diabetic nephropathy and a lower incidence of newly diagnosed diabetes.
• Vitamin E (400 IU/day for 4.5 years) did not significantly lower cardiovascular risk.

Conclusions:

• Ramipril is effective in preventing major adverse cardiovascular events and offers specific benefits for diabetic patients.
• Vitamin E supplementation, at the studied dose and duration, does not provide significant cardiovascular protection.
• ACE inhibition with ramipril represents a valuable strategy for managing cardiovascular risk in high-risk populations.